PubMed Health⌕ Search

Biomedical subjects

V Popovic

Publications and source records attributed to V Popovic.

88 records · Page 5Linked to original sources

Granulocyte transfusions in recovery of neutropenic rats from induced E. coli toxicemia.

Rats made transiently neutropenic by intra-arterial administration of vinblastine (3 mg/kg) and infected with E. coli (6.02+/-0.45 X 10(8), per animal) have a mortality rate of 90% within 48 h post infection. Multiple transfusions of large numbers of granulocytes (harvested from Deca-Durabolin treated donor rats) protected the neutropenic animals from sepsis. Out of a group of 11 rats, 10 recovered completely after repeated granulocyte transfusions.

Agranulocytosis↗

Recovery from experimental paraplegia after levodopa administration.

In decompression sickness and during some surgical procedures, air emboli that form sometimes cause serious damage if the gas bubbles find their way to the vital organs. Paralysis of the spinal cord is one of the most serious manifestations induced by air emboli. Exposure to compression chambers is effective in air emboli treatment, but availability of chambers is inadequate and the treatment is lengthy. Until now there has been no fully effective injectable agent that can remedy the damage caused by air embolization. In this work levodopa was chosen as an injectable drug that might help to improve recovery from experimental paraplegia because of the reported effects of levodopa on muscle tone, spasticity and locomotion. To induce air emboli, the descending aorta of rats was chronically cannulated. Two weeks later, after full recovery from surgery, air was injected through the chronically implanted cannula into unanesthetized rats (0.35 ml of air per 100 g, during 4 sec). The paraplegia (paralysis of both hind legs) was manifested 2-10 minutes later. Only animals that had total paraplegia, without any sensation, were used in the experiments. Levodopa was administered 2 minutes after paraplegia was established. The levodopa treatment was repeated each day during one week. After six days, ten levodopa treated (intra-arterially) animals in a group of twelve and six levodopa treated (intraperitoneally) animals in a group of eight recovered completely from paraplegia. In control groups only three from thirteen (untreated), or two from twelve (solvent administration) animals recovered from paraplegia.

Animals↗

Levodopa-enhanced recovery from paralysis induced by air embolism.

In this study levodopa was chosen as an agent that might ameliorate the clinical manifestations of paralysis induced by air embolism because of reported effects of this drug on muscle spasticity and locomotion. In order to induce air embolism, the aorta of rats was cannulated chronically. Fifteen days later, after full recovery of the animals, air was administered through the chronic cannula into the descending aorta of each rat (0.35 ml. of air per 100 Gm. during 4 seconds). The paralysis of both hind legs was observed one to 10 minutes later. Only animals that had total paralysis of both hind legs, without any sensation, were used in the experiments. levodopa was administered 2 minutes after experimentally induced paralysis. The levodopa treatment was repeated every day for 6 days. After 6 days, six levodopa-treated (intraperitoneally) animals in a group of eight and ten levodopa-treated (intra-arterially) animals in a group of 12 recovered fully from the paralysis. Only three animals in a group of 13 (untreated) or two animals in 12 (solvent administration) recovered without the levodopa treatment.

Animals↗

Techniques for induction of neutropenia and granulocytosis in rats.

After a single administration of vinblastine, rats develop profound neutropenia. The agranulocytosis lasts 3 days, and it is observed on the third, fourth and fifth day after vinblastine administration. The granulocytosis that develops on days 7-14 after vinblastine administration was significantly increased when androgenic steroids were administered. Deca-Durabolin induced greater granulocytosis than testosterone. The peak values were observed 10 and 12 days, respectively, after drug administration. All values of WBC's, granulocytes and hematocrit ratios were obtained in unanesthetized, unrestrained rats from an aortic cannula implanted at least 10 days prior to the experiment.

Agranulocytosis↗

Injectable agent for the treatment of air emboli-induced paraplegia in rats.

Rats with air emboli-induced paraplegia were treated with dialy levodopa injections (intra-arterially or intraperitoneally). Of the control animals, 20% fully recovered from paraplegia during a period of 7 d. Of the levodopa treated animals, 85% fully recovered during the same period. It appears, therefore, that levodopa might be one of the few injectable agents enhancing recovery from air-induced paraplegia, suggesting its possible use in decompression sickness.

Animals↗

Leptin and the pituitary.

Although leptin was originally viewed as an antiobesity hormone, it is now evident that it may have more pleiotropic actions. Experiments in rodents have shown that leptin activates the sympathetic nervous system, is involved in regulation of blood pressure, hematopoiesis, immune function, angiogenesis and brain, bone and pituitary development. Some biological effects expected based on observations in rodents, have so far not been seen in humans. Thus due to species differences in the role of leptin it is difficult to translate the data from rodents to human physiology. Hypothalamus is the primary brain site targeted by circulating leptin, secreted by fat cells. Leptin receptor has homology to members of class I cytokine receptor family, which may imply similarities in molecular events engaged by cytokines and leptin. In view of its cytokine-like properties it is likely that leptin produced and secreted outside of fat tissue i.e. in other tissues (CNS, pituitary, ovary, placenta, etc), is a paracrine regulator. Leptin receptor isoforms, long-signaling and short-nonsignaling, have been recently localized in human pituitaries. This opens the possibility of a direct action of leptin on the pituitary. However this appears to be quite complex and is species dependent. Leptin can be synthesized by normal and tumorous pituitary cells. Leptin protein expression in pituitary adenomas is decreased compared to that in normal pituitaries. Colocalization studies with leptin and anterior pituitary cells showed that 70% of ACTH cells are positive for leptin, 21% of GH cells, 29% of LH cells, 33% of FSH cells, 32% of TSH cells, 64% folliculo-stellate cells whereas very few PRL cells were positive (3%). Leptin is stored in secretory granules and secretory cells retain leptin in granules until stimulated. This follows a different secretory pathway than in adipocytes where upon synthesis leptin is immediately released. Question to be raised is does the pituitary contribute to the body leptin pool or is its action predominantly paracrine/autocrine? Clinically based evidence from studies performed in patients harboring different functional pituitary tumors causing a state of hormonal hypersecretion (acromegaly, prolactinomas, Cushing's disease) or hypopituitarism (due to non-functioning pituitary adenomas), are in favor of a paracrine/autocrine role of the pituitary leptin. Most of the studies have shown that the link between leptin, body composition and hormones of the pituitary is indirect. Thus changes in levels of circulating leptin are most likely due to changes in the metabolic and hormonal milieu during the chronic course of the disease or chronic treatment. Furthermore, circadian rhythm of leptin, its pulsatility and gender difference are preserved in hypopituitarism as well as in patients with functional pituitary adenomas implying that intact hypothalamic-pituitary function is not essential for leptin's circadian rhythm.

Acromegaly↗

Effect of 12 months of recombinant human growth hormone replacement therapy on insulin sensitivity in GH-deficient adults as determined by different methods.

BACKGROUND: Controversial results have been obtained in measuring insulin sensitivity (S(I)) during recombinant human growth hormone (rhGH) treatment in adult growth hormone deficient (GH-deficient) patients. AIMS: The aim of our study was to estimate S(I) before and during treatment using three different methods for quantifying insulin sensitivity in GH-deficient adults treated with rhGH. SETTINGS AND DESIGN: Twenty-one GH-deficient adults were treated with rhGH during 12 months. S(I) was estimated using Minimal model analysis, Homeostatic Model of Assessment (HOMA) and Quantitative Insulin Sensitivity Check Index (QUICKI) before and after 3, 6, 9 and 12 months of rhGH therapy. MATERIAL AND METHODS: Oral Glucose Tolerance Test (OGTT) and Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT) were performed in each patient at respective time intervals. QUICKI and HOMA were calculated using basal values of glucose and insulin from FSIGT. Minimal model computer analysis was calculated from glucose and insulin data obtained during FSIGT. STATISTICAL ANALYSIS: Area under the curve for glucose, insulin and C-peptide were calculated using trapezoidal rule from OGTT data. Differences and correlations were tested using ANOVA for repeated measures, Wilcoxon's matched-paired test, paired t-test, Pearson's correlation and Bland Altman plot. RESULTS: There were no significant changes in S(I) using Minimal model analysis and QUICKI during rhGH treatment. On the contrary, HOMA analysis indicated significant deterioration in S(I) after 12 months of therapy. CONCLUSION: Our study did not demonstrate any changes in S(I) using Minimal model and QUICKI analysis, while there was significant increase in insulin resistance using HOMA model. We suggest that the choice of method for the determination of S(I) may influence the interpretation of results concerning the effect of rhGH therapy on S(I) in GH-deficient adults.

Adult↗